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Abstract: The biological role and therapeutic potential of long non-coding RNAs (lncRNAs) in chronic
lymphocytic leukemia (CLL) are still open questions. Herein, we investigated the significance of the
lncRNA NEAT1 in CLL. We examined NEAT1 expression in 310 newly diagnosed Binet A patients,
in normal CD19+ B-cells, and other types of B-cell malignancies. Although global NEAT1 expression
level was not statistically different in CLL cells compared to normal B cells, the median ratio of
NEAT1_2 long isoform and global NEAT1 expression in CLL samples was significantly higher than in
other groups. NEAT1_2 was more expressed in patients carrying mutated IGHV genes. Concerning
cytogenetic aberrations, NEAT1_2 expression in CLL with trisomy 12 was lower with respect to
patients without alterations. Although global NEAT1 expression appeared not to be associated with
clinical outcome, patients with the lowest NEAT1_2 expression displayed the shortest time to first
treatment; however, a multivariate regression analysis showed that the NEAT1_2 risk model was not
independent from other known prognostic factors, particularly the IGHV mutational status. Overall,
our data prompt future studies to investigate whether the increased amount of the long NEAT1_2
isoform detected in CLL cells may have a specific role in the pathology of the disease.
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Chronic lymphocytic leukemia (CLL) has a highly heterogeneous clinical course, ranging from
an indolent behavior to an aggressive disease that needs prompt treatment in almost 30% of cases.
These differences have been associated with a number of markers of the leukemic cells, including
chromosomal aberrations, mutational status of the Immunoglobulin heavy chain variable region genes
(IGHV), TP53 inactivation, CD38 and ZAP-70 expression [1]. However, despite the availability of these
markers, the disease course remains somewhat unpredictable.
In the recent years, attention has been focused on long non-coding RNA (lncRNA), which are
involved in many biological processes, such as transcriptional gene regulation, cell development
and differentiation. Deregulation of lncRNAs has been demonstrated to be connected with tumor
formation, progression and metastasis in many types of cancers, including hematological malignancies,
although the information on a potential pathogenetic role in CLL is rather limited [2–5].
In this study, we focused on nuclear paraspeckle assembly transcript 1 (NEAT1), a well-known
lncRNA located on chromosome 11q13. NEAT1 is transcribed in two different isoforms: a canonically
polyadenylated short transcript of 3.7 kb (NEAT1_1), and a longer non-polyadenylated transcript
(NEAT1_2) of about 23 kb that includes entirely the short NEAT1_1 form. The two isoforms share a
common promoter but have an alternative transcription termination site. NEAT1_2 is an indispensable
structural component of paraspeckles (PSs), which are membraneless compartments of the nucleus [6].
Although their function is not fully defined, PSs are involved in stress response and influence gene
expression by regulating both transcription and pre-mRNA splicing events and by holding nuclear
mRNA for editing [7]. NEAT1_2 could indirectly control these events by modulating the functions
of PSs upon exposure to specific stresses [8]. Concerning NEAT1_1, even if it represents the most
abundant isoform found in all samples, its biological role has to be fully elucidated. Recent data
strongly suggested that it could be nonfunctional [8] leading to the hypothesis that NEAT1_1 keeps
the transcription of the NEAT1 locus active, guaranteeing a rapid switch to NEAT1_2 production in
response to stress.
NEAT1 deregulation has been reported in many types of solid tumors, where it is often associated
with a poor prognosis, and in hematological malignancies, where it appears to affect different biological
processes. Specifically, the aberrant expression of PML-RARα activity is correlated with NEAT1
downregulation in acute promyelocytic leukemia, suggesting that it may contribute to the impairment
of myeloid differentiation [9]. We recently reported that the expression of NEAT1 in multiple myeloma
(MM) is well above the normal controls, although this deregulation does not appear to correlate with
prognosis. However, the putative NEAT1 involvement in different mechanisms of cellular stress
response, such as the Unfolded Protein Response (UPR) and TP53 pathways, makes it a confident
candidate for a potential targeted therapy in the disease [10,11]. Moreover, the high NEAT1_1 levels
observed in MM suggest the possibility of NEAT1_1 involvement in PSs unrelated functions.
Information on NEAT1 expression and its possible deregulation in CLL is still lacking. Recently,
Blume et al reported that NEAT1 expression can be induced during DNA damage responses in CLL
cases with an intact TP53 function [12]. To gain further information on this issue, we investigated
NEAT1 expression in 310 newly diagnosed Binet A patients prospectively enrolled in an observational
multicenter study (clinicaltrial.gov #NCT00917540 from January 2007 to May 2011) (Table 1) [13]. The
National Cancer Institute (NCI)-sponsored Working Group guidelines were followed for diagnosis and
staging [1]. Eighty four of these 310 cases, who had less than 5.0 × 106 monoclonal B lymphocytes/L
in the blood, were reclassified and diagnosed as monoclonal B-lymphocytosis (MBL) in accordance
with the more recent International Workshop on Chronic Lymphocytic Leukemia (IWCLL) diagnostic
criteria [1]. Median follow-up time was 76 months (range, 1–130 months). Highly enriched CD19+ CLL
cells were characterized for IGHV mutational status and cytogenetic alterations, including deletion
of 13q (del13), 11q (del11), and 17p (del17) and trisomy of chromosome 12 (12+), as previously
reported [14]. NOTCH1 mutations were also investigated as described [15].
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Table 1. Features of 310 CLL samples.
Parameter Test Cohort
Number of patients 310
Median age, years (range) 61 (18-71)
Male gender (%) 182 (59)
MBL (%) 84 (27)
IGHV unmutated (%; n.d.) 101 (34; 15)
absence of FISH abnormalities a (n.d.) 114 (7)
del13 b (n.d.) 146 (8)
12+ (n.d.) 32 (7)
del11q (n.d.) 19 (7)
del17p (n.d.) 4 (7)
NOTCH1 mutation (n.d.) 46 (1)
a Samples with none of classical cytogenetic aberrations detected by FISH; b Biallelic 13q deletion was present in
18 samples.
In addition, we evaluated NEAT1 expression also in other types of hematological tumors, including
B-cell acute lymphoid leukemia (ALL), acute and chronic myeloid leukemia (AML and CML), MM, B
cell-lymphoma cell lines, and different types of normal B-cell populations, i.e., 27 samples including
normal peripheral blood B-cells (pBC) and naïve and memory B cells purified from spleen or tonsils as
specified elsewhere [14]. All the statistical tests were performed using appropriate R functions setting
p-value < 0.01 as cutoff for significance.
For NEAT1 determination a quantitative real-time PCR (qRT-PCR) approach was used that was
capable of discriminating the NEAT1 (NEAT1_1 and NEAT1_2) global expression from that of the
NEAT1_2 isoform [11]. Global NEAT1 expression was also confirmed by RNA FISH (Supplementary
Figure S1).
The NEAT1 expression levels in CLL cells are shown in Figure 1A also in comparison with
those found in normal B-cell populations and in the malignant cells from the other hematological
tumors. NEAT1 and NEAT1_2 expression levels were not statistically different in CLL cells compared
to normal B cells. No differences could be detected even when CLL cells were compared separately
with either normal naïve or memory B cells, which are considered closer to CLL cells (Supplementary
Figure S2) [14,16]. CLL cells expressed significantly more NEAT1 than those of the other hematological
neoplasias with the exception of MM cells, which are known to express high levels of this lncRNA
(Figure 1a, left panel) [17]. Next, we verified the correlation between the two NEAT1 isoforms in
all the populations analyzed and, with the exception of the small group of B-lymphoma cell lines,
we found that NEAT1_2 expression levels positively correlated with those of NEAT1_1 (Figure 1b).
Interestingly, CLL cells expressed the highest amount of NEAT1_2 isoform compared to the other cell
types (Figure 1a, right panel). In particular, the median ratio of NEAT1_2 and NEAT1 expression in
CLL samples (40%) was significantly higher than in the other groups (range 5–21%, Figure 1c).
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Figure 1. NEAT1 and NEAT1_2 expression levels in normal B-cells and in B-cell malignancies. (a) 
Boxplots of NEAT1 and NEAT1_2 expression levels evaluated by qRT-PCR in 27 normal B-cells, 310 
CLL, 82 MM, 16 ALL, 16 CML, and 20 AML samples, and 7 B-lymphoma cell lines (OCILY7, MAVER1, 
JEKO, MINO, SULTAN, P3HR1, and NAMALWA). Expression data are reported as Ct referred to 
GAPDH housekeeping gene. Significant differences versus CLL group are indicated by an asterisk 
(Benjamini-Hochberg adjusted Dunn’s test, p < 0.01). (b) Pearson’s correlation on NEAT1_1 (x-axis) 
and NEAT1_2 (y-axis) expression level expressed as Ct. NEAT1_1 expression values are inferred as 
described in Appendix B. Correlation coefficient and p-values are reported in each plot. (c) Ratios of 
NEAT1_2 and total NEAT1 expression level; range, average and standard deviation are reported for 
each group. a Median value of the ratios of NEAT1_2 and NEAT1 expression level evaluated for each 
sample in the specified subgroups. Significant differences versus CLL group are indicated by an 
asterisk (Benjamini-Hochberg adjusted Dunn’s test, p < 0.01). b Significant differences of NEAT1 and 
NEAT1_2 expression levels (Wilcoxon test). 
Figure 1. NEAT1 and NEAT1_2 expression levels in normal B-cells and in B-cell malignancies.
(a) Boxplots of NEAT1 and NEAT1_2 expression levels evaluated by qRT-PCR in 27 normal B-cells, 310
CLL, 82 MM, 16 ALL, 16 CML, and 20 AML samples, and 7 B-lymphoma cell lines (OCILY7, MAVER1,
JEKO, MINO, SULTAN, P3HR1, and NAMALWA). Expression data are reported as Ct referred to
GAPDH housekeeping gene. Significant differences versus CLL group are indicated by an asterisk
(Benjamini-Hochberg adjusted Dunn’s test, p < 0.01). (b) Pearson’s correlation on NEAT1_1 (x-axis)
and NEAT1_2 (y-axis) expression level expressed as Ct. NEAT1_1 expression v lues are inferred as
described in Appe ix B. Correlation coefficient d p- alues are reported in each plot. (c) Ratios
of NEAT1_2 and total NEAT1 expression level; range, average and standard deviation are reported
for each group. a Median value of the ratios of NEAT1_2 and NEAT1 expression level evaluated for
each sample in the specified subgroups. Significant differences versus CLL group are indicated by an
asterisk (Benjamini-Hochberg adjusted Dunn’s test, p < 0.01). b Significant differences of NEAT1 and
NEAT1_2 expression levels (Wilcoxon test).
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Although, on the whole, our CLL series had a median NEAT1 expression similar to that of
normal B cells, a proportion of samples showed high expression levels of global NEAT1 (Figure 1a, left
panel) or NEAT1_2 (Figure 1a, right panel) long isoform. Prompted by such findings, we investigated
whether differences in NEAT1 expression could correlate with other characteristics, which usually
define different CLL prognostic groups. The global NEAT1 expression was comparable in CLL and in
MBL cases, and there was no significant difference in IGHV-mutated (M) or -unmutated (UM) cases
or between cases with different cytogenetic alterations (Figure 2a, upper panel; and Supplementary
Figure S3). In contrast, the expression of the long NEAT1_2 isoform was significantly different in CLL
subgroups stratified according to prognostic markers (Figure 2a). Specifically, NEAT1_2 was more
expressed in the IGHV-M than in the IGHV-UM cases and in CLL cases without cytogenetic aberrations
or with the 13q deletion, whereas it was significantly lower in patients with 12+ (Figure 2a, lower
panel). No difference in NEAT1_2 expression was observed in the groups with or without NOTCH1
mutations (Figure 2a, upper panel) [15]. As for global NEAT1, NEAT1_1 isoform did not show any
significantly differential expression in all the subgroups investigated (data not shown).
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In addition, we investigated the possible association between NEAT1 and TP53 expression, 
based on data reporting NEAT1 as an effector of p53 protein, likely playing an important role in 
suppressing transformation in response to stress signals [18]. To do this, we focused our attention on 
cases harboring del17p in our series. Although the analysis has been limited only to the four available 
patients with del17p, our results showed that neither global NEAT1 nor NEAT1_2 expression levels 
in CLL were significantly lower than the ones detected in patients without del17p (n = 299; NEAT1 
with del17p: 1.067 ± 1.013 vs without del17p 1.628 ± 1.229, p = 0.25; NEAT1_2 with del17p: 2.679 ± 
Figure 2. NEAT1 expression level in CLL. (a) Wilcoxon test results comparing CLL subgroup defined
by the indicated parameter; p-value < 0.01 was considered significant (a Kruskal-Wallis test). Below,
stripchart of NEAT1_2 expression in CLL subgroups defined by mutational IGVH status or the presence
of the main chromosomal abnormalities detected by FISH; none = absence of FISH abnormalities
(dashed line for p < 0.01, Dunn’s test). (b) Kaplan–Meier estimated curves of the six groups defined
by NEAT1_2 expression levels. (c) Multivariate analysis comparing the NEAT1_2 risk model with
prognostic variables or with MBL status in CLL series. b del17 or del11 CLL vs. others.
In addition, e investigate t e possi l ass ci ti t a 53 ex ressi ,
based on data reporting E T1 as an effector of p53 protein, likely playing an i portant role in
suppressing tr to stress signals [18]. To do this, we focused our attention
on cases ha boring del17p in our eries. Although the analysis has been limited only to the four
available pa ients with del17p, our results showed at neither global NEAT1 nor NEAT1_2 expression
levels in CLL were significantly lower than the ones etected i patients without del17p (n = 299;
NEAT1 with del1 p: 67 ± 1.013 vs without del17p .6 8 ± 1.229, p = 0.25; NEAT1_2 with del17p:
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2.679 ± 0.557 vs. without del17p 3.154 ± 1.576, p = 0.34). To better characterize the TP53 status in
these 4 patients, we sequenced the gene and found TP53 mutations in all samples, with a Variant
Allele Frequency (VAF) higher than 95% in three cases (Supplementary Table S1). Therefore, in these
4 patients, TP53 gene appears to be completely disrupted. Overall, these results are in keeping with
data by Blume et al. [12], showing that basal NEAT1 expression level is quite similar in CLL patients
with a wild-type TP53 status or in those carrying TP53 alteration (i.e., mutation and/or deletion). Next,
we evaluated whether mutated TP53 proteins found in our 4 patients were capable to activate NEAT1
transcription, by exploiting a yeast-based P53 functional assay (Appendix A) [19–21]. Firstly, a new
reporter yeast strain (yLFM-NEAT1) in which the p53 response element (RE) from the NEAT1 target
gene (5’-GAGCAAGCCTGGGCTTGCCA-3’) [18] controls the expression of the LUC1 reporter gene,
was constructed. Whereas wild-type P53 confirmed the ability to activate transcription in yLFM-NEAT1
(Supplementary Figure S4A), all four P53 mutants encoded by the corresponding TP53 mutations
failed to activate transcription in yLFM-NEAT1 (Supplementary Figure S4B). Therefore, it is possible
to speculate that a significantly lower NEAT1 expression level in patients harbouring a completely
inactive TP53 mutation with respect to patients without TP53 alterations is detectable only upon P53
induction by stress, as also suggested by Blume et al. [12].
Lastly, we correlated NEAT1 expression levels with time to first treatment (TTFT) as clinical
outcome. To this end, patients were subdivided into sextiles based on global NEAT1 or NEAT1_2
specific expression by leukemic cells. We found that NEAT1 expression was not associated with
prognosis. Patients with the lowest NEAT1_2 expression (1st sextile) displayed the shortest TTFT if
compared with all the other samples (Figure 2b); however, a multivariate regression analysis showed
that the NEAT1_2 risk model was not independent from other known prognostic factors, particularly
the IGHV mutational status (Figure 2c).
In conclusion, our study, performed in a large and well-characterized cohort of early stage
Binet A CLL patients, has provided evidence that NEAT1 expression levels are quite heterogeneous
irrespectively of cytogenetic groups or clinical outcome. Based on these findings and the suggestion
that the two NEAT1 transcripts may have different biological roles [8,22], it would be of interest to
investigate whether the increased amount of the long NEAT1_2 isoform detected in CLL cells may
have a specific role in the pathology.
Supplementary Materials: The following are available online at http://www.mdpi.com/2311-553X/6/1/11/s1,
Figure S1: NEAT1 RNA FISH detection, Figure S2: NEAT1 expression level in CLL, Figure S3: Stripchart of NEAT1
expression in CLL subgroup, Figure S4: yeast-based P53 functional assay, Table S1: Molecular features of the four
CLL patients showing the concomitant presence of del17p and TP53 mutation.
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Appendix A
The new haploid S. cerevisiae yeast strain yLFM-Neat1 was generated using the delitto perfetto
approach [21] by the genomic cloning of the human NEAT1 promoter P53 RE [-1458 bp from the
transcription start site (TSS): 5’-GAGCAAGCCTGGGCTTGCCA-3’] [18]. The available yeast strains
yLFM-P21-5’ and yLFM-mir-34a [19] were also used for comparison. The haploid strain yIG397 was
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used for the cloning of the TP53 mutations in a pLS-based yeast expression vector; yeast manipulations
and the functional assay were performed as previously described [20].
Appendix B
Reverse transcription and quantitative PCR. Total RNA was extracted using TRIzol®Reagent
(Invitrogen) according to manufacturer’s instructions. The purity and concentration of total RNA
was determined by the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA,
USA). The ratios of absorption (260 nm/280 nm) of all samples were between 1.8 and 2.0. cDNA was
synthesized from 500 ng of total RNA with random primers using the High Capacity cDNA Reverse
Transcriptase Kit (Invitrogen, Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s
instructions. To evaluate the expression levels of listed genes, RT-PCR was performed using SYBR
green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) after optimization of the primer
conditions. 10 ng of reverse-transcribed RNAs were mixed with 300 nM of specific forward and reverse
primers in a final volume of 10 µl. RT-PCR was performed on an Applied Biosystems StepOnePlus
Real-Time PCR system for 40 cycles. Data were analyzed using the ∆Ct method to measure the relative
changes in each gene’s expression compared with GAPDH expression. To determine RNA levels by
qPCR, the following primers were used:
Primer Name Sequence (5’-3’)
NEAT1 FW 5’-GCCTTGTAGATGGAGCTTGC-3’
NEAT1 RW 5’-GCACAACACAATGACACCCT-3’
NEAT1_2 FW 5′-GGCCAGAGCTTTGTTGCTTC-3′
NEAT1_2 RW 5′-GGTGCGGGCACTTACTTACT-3’
GAPDH FW 5’-ACAGTCAGCCGCATCTTCTT-3’
GAPDH RW 5’-AATGAAGGGGTCATTGATGG-3’
RT-PCR primers efficiency. To estimate RT-PCR primers efficiency, we followed the method based
on standard curve assessment, which relies on repeating the PCR reaction with known amounts of
template. Ct values versus template concentration input (i.e., reverse transcribed total RNA expressed
as log values) were plotted to calculate the slope. Efficiency percentage value, E (%), was defined as
E (%) = (10−1/Slope − 1) × 100
in which Slope was derived from the regression curve calculated between the template log values and
all the average Ct values [23,24]. In our study, we evaluated the following E (%) for each couple of
primers: GAPDH 100%, NEAT1 106% and NEAT1_2 120%. Amplification values derived from RT-PCR
analysis were adjusted taking into consideration the efficiency of both NEAT1 couples of primer and
the adjusted results were used for all experiments. NEAT1_1 Ct expression values were inferred as the
difference between adjusted fold change of NEAT1 and NEAT1_2.
Ratio calculations. The ratios of NEAT1_2 and total NEAT1 expression level was evaluated by
calculating, for each sample, the ratio in the corresponding adjusted fold change; then, the median
value for each group was reported.
Statistical analysis. Conventional statistical tests were applied as reported in the manuscript using
standard functions in base R package (Pearson coefficient to assess sample correlation; Wilcoxon
rank-sum, Kruskal-Wallis and Dunn’s test to assess whether the samples originate from the same
distribution). We used the Cox proportional hazards model to test the association between NEAT1
expression levels, assumed as continuous variables or stratified into n (up to six) equally parted groups
and time to first treatment (TTFT) as clinical outcome.
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